United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 2 minute read Pharma Industry News Britannia Pharmaceuticals’ apomorphine shows promise in Phase 3 TOLEDO trial for Parkinson’s disease Britannia Pharmaceuticals, a subsidiary of the British pharma group, has announced successful Phase 3 results for its APO-go/MOVAPO… bypharmanewsdailyAugust 5, 2018
